The introduction of this swine vaccine enables Intervet/Schering-Plough Animal Health to capitalise on its extensive expertise and years of technical support in the E. coli and Clostridium perfringens markets, working with veterinarians for the benefit of the swine industry. Multivalent vaccine formulation
Dr. Marc Dickie, recently appointed as Head of the Global Swine business unit for Intervet/Schering-Plough Animal Health, is excited about the introduction of PorcilisÂ® COLI 6C: â€œThis product introduction enables our company to market the multivalent vaccine formulation for control of E. coli and Clostridium perfringens with 4 antigens of E. coli and toxoids from 3 strains of Clostridium perfringens.
Moreover, we can market this vaccine in conjunction with our monovalent E. coli vaccine, PorcilisÂ® Porcoli DF. This offers veterinarians and producers more options to choose the most appropriate vaccine for specific enteric disease situations on each farm.â€
The new combination Intervet/Schering-Plough Animal Health, resulting from Schering-Plough’s acquisition of the Intervet animal health business in October 2007, strengthens the animal health portfolio in several areas and brings together complementary lines of pharmaceuticals, biologicals and an enhanced science and technology platform. On-going commitment
This ensures an on-going commitment to meet the challenges of the various species segments. Intervet/Schering-Plough Animal Health is not only the world market leader in the production of animal health vaccines, but is also one of the world’s leaders in the field of animal health. Related Website
â€¢ Intervet Schering-Plough Animal Health Click here for the free Pig Progress newsletter